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Abstract
G-protein-coupled receptors (GPCRs) are known to activate both G protein- and β-arrestin-dependent signalling
cascades. The initiation of mitogen-activated protein kinase (MAPK) pathways is a key downstream event in the
control of cellular functions including proliferation, differentiation, migration and apoptosis. Both G proteins and β-
arrestins have been reported to mediate context-specific activation of ERK1/2, p38 and JNK MAPKs. Recently, the
activation of ERK5 MAPK by Gq-coupled receptors has been described to involve a direct interaction between Gαq
and two novel effectors, PKCζ and MEK5. However, the possible contribution of β-arrestin towards this pathway has
not yet been addressed. In the present work we sought to investigate the role of receptor internalization processes
and β-arrestin recruitment in the activation of ERK5 by Gq-coupled GPCRs. Our results show that ERK5 activation is
independent of M1 or M3 muscarinic receptor internalization. Furthermore, we demonstrate that phosphorylation-
deficient muscarinic M1 and M3 receptors are still able to fully activate the ERK5 pathway, despite their reported
inability to recruit β-arrestins. Indeed, the overexpression of Gαq, but not that of β-arrestin1 or β-arrestin2, was found
to potently enhance ERK5 activation by GPCRs, whereas silencing of β-arrestin2 expression did not affect the
activation of this pathway. Finally, we show that a β-arrestin-biased mutant form of angiotensin II (SII; Sar1-Ile4-Ile8
AngII) failed to promote ERK5 phosphorylation in primary cardiac fibroblasts, as compared to the natural ligand.
Overall, this study shows that the activation of ERK5 MAPK by model Gq-coupled GPCRs does not depend on
receptor internalization, β-arrestin recruitment or receptor phosphorylation but rather is dependent on Gαq-signalling.
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Introduction
G-protein-coupled receptors (GPCRs) are the largest and
most versatile family of transmembrane receptor in mammalian
cells [1]. The classical model for GPCR action involves G
protein-mediated signal transduction and progressive
desensitisation mediated by GPCR kinases (GRKs) and β-
arrestins. GRKs are known to phosphorylate the internal loops
of activated receptors thus creating recognition sites for high-
affinity binding of β-arrestins. These proteins uncouple
receptors from heterotrimeric G proteins and promote receptor
internalization [2]. However, over the last few years there has
been a new appreciation of the capacity of β-arrestins to act as
multifunctional adaptor proteins that have the ability to couple
GPCRs to numerous signalling components such as mitogen-
activated protein kinases (MAPKs), Src, nuclear factor-κB (NF-
κB) and phosphoinositide 3-kinase (PI3K) [3]. The actions of G
proteins and β-arrestins are diverse and are often spatially and
temporarily segregated. For instance, the contribution of G
protein/β-arrestin towards the activation of ERK1/2 by
angiotensin II is additive but differs in kinetics, timeframe and
localisation [4]. Upon stimulation of the AT1A receptor, ERK1/2
is immediately, but transiently, activated via the G protein-
dependent pathway, whereas β-arrestin2-mediated ERK1/2
activation is relatively slow but persistent. Interestingly, G
protein-activated ERK1/2 is found in the nucleus whereas it
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localises in the cytoplasm upon β-arrestin activation.
Additionally, mutational studies have determined the
independence of both pathways with mutant versions of the
angiotensin AT1A receptor that are unable to couple to G
proteins while still able to recruit β-arrestins [5,6].
Activated Gq/11-coupled GPCRs trigger different signals that
have been implicated in the control of MAPK pathways,
including ERK1/2, p38, JNK and ERK5 cascades. Both Gq-
dependent and β-arrestin-dependent mechanisms have been
described for the activation of MAPKs, except from the most
recently described ERK5 [3]. The GPCR-initiated pathway
leading to ERK5 does not involve the classical routes (Ras,
Rho, Rac, and/or Cdc42) for the activation of MAPK by GPCR
[7]. Recently, our group described the molecular mechanism
for the activation of ERK5 by the Gq-coupled M1 muscarinic
receptor in epithelial cells [8]. This pathway did not require
PLCβ activity and involved the atypical protein kinase C zeta
(PKCζ) and the MAPKK MEK5 as two novel effectors of Gαq.
Such process was found to be conserved in the heart and to be
important in the development of angiotensin II-induced
hypertrophic programmes in vivo [9]. Thus, it was shown that
Gq-coupled muscarinic and angiotensin II receptors activate
ERK5 through a similar mechanism but the contribution of β-
arrestin towards the novel pathway was not addressed.
Therefore, in the present study we have aimed to establish
relative contributions of Gαq- versus β-arrestin-dependent
signalling in the activation of ERK5.
Materials and Methods
Ethics statement
Mice for the isolation of primary cultures were maintained
under pathogen-free conditions, and all of the experiments
were performed in accordance with the guidelines of the
European Convention for the Protection of Vertebrate Animals
used for Experimental and Other Scientific Purposes (Directive
86/609/ EEC) and with the authorization of the Bioethical
Committee of the Universidad Autónoma de Madrid
(CEI-21-440).
Materials
The cDNA of Gαq was kindly provided by Dr. Anna Aragay
(CSIC Barcelona, Spain). β-arrestin1-FLAG was provided by V.
Gurevich (Vanderbilt University, Nashville, USA) and β-
arrestin2-GFP was a gift from Dr. J.L. Benovic (Kimmel Cancer
Center, Philadelphia, USA). The cDNA encoding HA-ERK5 has
been previously described [8]. NIH-3T3 fibroblasts expressing
approximately 20,000 human M1 muscarinic receptors per cell,
designated NIH-3T3-M1 cells, were kindly provided by Dr. J.S.
Gutkind (NIH, Bethesda, MD, USA). CHO-M3 internalization-
deficient cells expressing a mutant version of the muscarinic
M3 receptor that cannot internalize (motif SASS to AAAA) were
previously characterised [10]. CHO-M3 wild-type, CHO-M3
phospho-deficient, CHO-M1 wild-type and CHO-M1 phospho-
deficient cells were previously generated [11] in the Flp-In
genetic background to guarantee equal expression of receptors
amongst the different cell lines [12]. Culture media and
Lipofectamine were from Life Technologies Inc. (Gaithersburg,
MD, USA). The monoclonal antibody against Gαq was from
Abnova. Rabbit anti-phospho-ERK5 antibody (p-Thr218/p-
Tyr220) was purchased from Invitrogen. Anti-ERK5 and anti
phospho-ERK1/2 were from Cell Signalling. Anti-ERK1 and
anti-ERK2 antibodies were from Santa Cruz. Anti-alpha tubulin
and anti-FLAG were from Sigma. Anti-GFP was from Roche.
Anti-clathrin heavy chain was from BD Transduction.
Carbachol, acetylcholine and angiotensin II were from Sigma,
and SII (Sar1-Ile4-Ile8 Ang II) was from Bachem. All other
reagents were of the highest commercially available grades.
Cell line culture and treatment
NIH-3T3-Ml and CHO cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
(v/v) Newborn serum (Gibco) or fetal bovine serum (Sigm-
Aldrich, St. Louis, MO, USA), respectively, at 37°C in a
humidified 5% CO2 atmosphere. The desired cell type was
stimulated with different muscarinic receptor ligands (carbachol
or acetylcholine) at 37°C in serum-free DMEM media, at the
specified doses and during the indicated time periods. It is
noteworthy that acetylcholine and carbachol are chemically
equivalent species and, in our hands, have been proven
interchangeable in their ability to promote ERK5 activation. The
cells were serum-starved for 5-6 h before ligand addition to
minimise basal kinase activity. CHO cells (70-80% confluent
monolayers in 60 mm dishes) were transiently transfected with
the desired combinations of cDNA constructs using the
Lipofectamine/Plus method, following manufacturer’s
instructions. Empty vector was added to keep the total amount
of DNA per dish constant. Assays were performed 24h after
transfection. Transient expression of the desired proteins was
confirmed by immunoblot analysis of whole-cell lysates using
specific antisera, as described below.
Primary cultures of neonatal fibroblasts were prepared from
C57BL/6J mice by dissociation of neonatal (1-2 days) hearts.
After excised, hearts were kept in Ca++-free medium at 4°C and
were mechanically disaggregated using a sterile scalpel blade.
For the chemical disaggregation the tissue was transferred to a
culture flask (T25) and kept in trypsin (0.05%) and type II
collagenase (Worthington) for 15min at 37°C after which the
supernatant was collected and mixed with medium with calcium
to stop the reaction. The macroscopical tissue fragments that
remained in the flask were further disaggregation in up to 5
trypsinization steps. Each medium collected was centrifuged
(5min, 1500 r.p.m.), resuspended in medium supplemented
with 10% FBS and kept at 37°C. Cells were plated and
incubated for 2h to allow for non-myocytes to attach, after
which time the medium containing cardiac myocytes was
discarded. Cardiac fibroblasts were expanded in DMEM
supplemented with 10% FBS and passed twice before the
assay to remove contamination by endothelial cells. Cells were
stimulated with angiotensin II (100 nM) or SII (Sar1-Ile4-Ile8
(SII) Ang II, 10µM) as previously described [13] in serum-free
media, during the indicated time periods. In order to minimise
ERK5 basal kinase activity before ligand addition, cells were
serum-starved for 5-6 h. Alternatively, to assess ERK1/2
activation cells were starved for 16h, treated with specific
MEK1/2 inhibitor (PD98059, 50µM, Cell signalling) for 30
ERK5 Activation and β-Arrestin
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minutes, washed in PBS and let stand in serum-free medium
for another 30 minutes before ligand stimulation.
Radioligand binding assays
Expression of cell surface muscarinic receptors after
exposure to carbachol for different times was determined as
described previously [14] except that saturating concentrations
(0.5 nM) of the muscarinic antagonist [3H]-NMS were used in
incubations with whole cells for 120 min at 4°C.
siRNA-mediated protein silencing
NIH-3T3-M1 cells were reverse-transfected using siRNA
specific oligos for clathrin (mouse CLTC, heavy chain, on-
target plus SMARTpool), or β-arrestin2 (mouse Arrb2, on-target
plus SMARTpool) purchased from Dharmacon (Roche, Palo
Alto, CA). Scrambled oligos were purchased from Ambion to
serve as negative control. siRNAs were transfected using
DharmaFECT 1 reagent (Dharmacon) to reach a final
concentrations of 100/250nM. Specific antibodies were utilised
to assess effective knockdown by Western blot.
Determination of MAPK stimulation
Activation of endogenous ERK5 was detected in NIH-3T3-
M1 cells and in primary cardiac fibroblasts by Western blot
analysis of cell lysates with a phosphospecific anti-ERK5
antibody. In CHO cell lines, due to the low ERK5 endogenous
levels, HA-tagged ERK5 was transfected and
immunoprecipitated with anti-HA agarose beads (Santa Cruz).
Immunoprecipitates were washed 6 times in lysis buffer (50
mM Tris-HCl, 150 mM NaCl, 1% (w/v) Nonidet P-40, 0.25%
(w/v) sodium deoxycholate, 1 mM EGTA, 1 mM NaF,
supplemented with 1 mM sodium orthovanadate plus a mixture
of protease inhibitors) at 4°C. Lysates were resolved by 8%
SDS-PAGE and subjected to immunoblot analysis as
previously described [8] and the activation state of ERK5 was
measured. To obtain cell lysates, cells were washed with ice-
cold PBS-buffer plus 1mM sodium orthovanadate and
subsequently solubilised in lysis buffer (50mM Tris-HCl,
150mM NaCl, 1% (w/v) Nonidet P-40, 0.25% (w/v) sodium
deoxycholate, 1mM EGTA, 1mM NaF, supplemented with 1
mM sodium orthovanadate plus a mixture of protease
inhibitors). Lysates were resolved by 6-10% SDS-PAGE and
subjected to immunoblot analysis. All blots were developed
using the chemiluminescence method (ECL, Amersham
Pharmacia Biotech, UK). Bands were quantified by laser-
scanner densitometry and the amount of phospho-ERK5
protein normalised to the amount of the total ERK5 protein, as
assessed by the specific antibodies. The activation of the
ERK1/2 pathway was determined as previously reported [8].
Statistical analysis was performed using the two-tailed
Student’s T-test, as indicated.
Results
Since β-arrestin has been recently proposed as an
alternative signalling node to heterotrimeric G proteins, it is
essential to ascertain whether a known GPCR-initiated
pathway like ERK5 is equally or differentially activated by these
two signalling players.
ERK5 activation by Gq-coupled GPCR does not require
receptor internalization
In order to facilitate the study of the mechanistic basis of
GPCR-ERK5 activation we initially utilised different cell lines
stably expressing Gq-coupled (muscarinic) receptors. This has
been widely proven to be the most successful experimental
approach to study ERK5 phosphorylation using the currently
available detection methods. In particular, the NIH-3T3 cell line
that stably overexpresses the human M1 muscarinic receptor
has been extensively used to detect endogenous ERK5
activation by us [8,9] and others [7].
Upon activation, GPCR internalize in a process that will lead
to recycling or degradation of the receptor. These receptor
trafficking processes have been reported to also provide
alternative ways for signalling propagation via β-arrestin [3].
Since β-arrestin recruitment leads to GPCR internalization in a
process where clathrin plays a key role [2,15], we determined
the activation of the ERK5 pathway in a clathrin knock-down
scenario. Thus, NIH-3T3-M1 cells were pre-treated with
scrambled siRNA or clathrin-targeting oligonucleotides and
stimulated with the muscarinic agonist carbachol for 30 minutes
(Figure 1A). Results indicated that ERK5 phosphorylation was
unaffected in the absence of clathrin (95% knock-down
efficiency, as quantified in Figure 1B) thus suggesting that
clathrin-mediated M1 receptor internalization is likely not
required for this process. Although the primary internalization
mechanisms for muscarinic Gq-coupled receptors are clathrin-
dependent [16,17], alternative processes have also been
reported [18]. To assess the contribution of clathrin-
independent mechanisms towards the ERK5 pathway, we
utilised a CHO cell line that overexpresses an internalization-
deficient mutant M3 muscarinic receptor. This receptor
harbours several mutations on the third internal loop (motif
SASS to AAAA) that prevent trafficking into endosomes [10].
We transfected HA-tagged ERK5 into CHO-M3 and CHO-M3-
internalization-deficient cells and stimulated with carbachol at
different times. Interestingly, we detected an increased and
sustained activation of ERK5 by the internalization-deficient
mutant compared to control (Figure 2A). The inability of the
activated mutant receptor to internalize was also confirmed
(Figure 2B). Collectively, these findings suggest that ERK5
activation by Gq-coupled muscarinic receptors occurs
independently of receptor internalization.
ERK5 activation by Gq-coupled GPCR does not involve
receptor phosphorylation or β-arrestin recruitment
β-arrestin is generally known to be recruited to GPCRs
through a mechanism dependent the phosphorylation of the
receptor. Thus, the translocation of arrestins to the plasma
membrane occurs through the recognition of phosphorylation
sites on the internal loops and C-terminal tails of receptors.
Since ERK5 activation does not seem to depend on receptor
internalization, if β-arrestin participates in this pathway, this
would not occur in the endosomes. However, it remained the
possibility that β-arrestin could initiate pathways leading to
ERK5 Activation and β-Arrestin
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Figure 1.  Gq-coupled muscarinic receptor-induced activation of the ERK5 pathway is clathrin-independent.  NIH-3T3 cells
stably overexpressing the muscarinic M1 receptor (NIH-3T3-M1 cells) were transfected with siRNA oligonucleotides targeting
clathrin heavy chain or non-targeting scrambled oligonucleotides (250nM) as detailed in the Materials and Methods section. After
72h of incubation, cells were serum-starved for 5h and challenged with carbachol (10µM) for the indicated times. (A) Endogenous
ERK5 phosphorylation was assessed in cell lysates with a phospho-ERK5 specific antibody. Data (mean +/- SEM of 3 independent
experiments) were normalised using ERK5 as loading control and expressed as fold-induction over basal conditions. (B) Clathrin
expression levels were also determined and quantified to estimate the overall efficiency of protein silencing. Data (mean +/- SEM of
3 independent experiments) were normalised using α-tubulin as loading control and expressed as the relative difference (%) to
control.
doi: 10.1371/journal.pone.0084174.g001
Figure 2.  Gq-coupled muscarinic receptor-induced activation of the ERK5 pathway does not require receptor
internalization.  (A) CHO cells stably overexpressing wild-type muscarinic M3 receptor or internalization-deficient M3 receptor
(SASS motif mutant, characterised in [10]) were transfected with HA-ERK5. Twenty-four hours after transfection, cells were serum-
starved for 2h and stimulated with carbachol (10µM). HA-ERK5 was immunoprecipitated with an anti-HA agarose-conjugated
antibody as detailed in the Materials and Methods section. ERK5 phosphorylation was assessed in the immunoprecipitate using a
phosphospecific antibody. Data (mean +/- SEM of 3 independent experiments) were normalised using HA-ERK5 as loading control
and expressed as fold-induction over basal conditions (*p<0.05, two-tailed T-test). (B) Quantification of cell surface receptor density
was performed through [3H]-NMS binding at 4°C. The two cell types utilised in (A) were serum-starved for 2h and stimulated with
carbachol (100µM) for 30 minutes. Data were normalised to unspecific binding (atropine treatment) and binding percentage was
expressed as the mean +/- SEM of 3 independent experiments.
doi: 10.1371/journal.pone.0084174.g002
ERK5 Activation and β-Arrestin
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ERK5 activation from the plasma membrane. In order to
ascertain this, we utilised a CHO cell line overexpressing a
phospho-deficient muscarinic M3 mutant receptor. This
receptor, in which all the phosphorylatable serines within the
internal loops are mutated to alanine, has been described to
have a significantly reduced ability to recruit β-arrestins in the
same cell line used in our study but to be otherwise functional
[11]. Notably, the amplitude of time-dependent ERK5
phosphorylation upon acetylcholine treatment was augmented
by the phosphodeficient M3 receptor compared to the wild-type
form of the receptor (Figure 3A). To further confirm this, we
used a similar phosphodeficient version of the M1 receptor and
stimulated for 15 minutes with sub-maximal doses of
acetylcholine in order to highlight the differences in ERK5
activation by wild-type or mutant receptor. Indeed, we observed
a clear enhancement of ERK5 activation by the
phosphodeficient mutant M1 receptor (Figure 3B). Taken
together, these data suggest that receptor phosphorylation and
the subsequent recruitment of β-arrestins are not involved in
ERK5 activation by Gq-coupled muscarinic GPCRs.
ERK5 activation by GPCR is Gαq-biased
The data above indicated that Gq-initiated signalling is the
key participant in ERK5 activation by muscarinic Gq-coupled
GPCR. We sought to confirm this notion by studying the
activation of ERK5 in a Gαq-enriched cell population. In these
circumstances, Gq-dependent pathways would be potentiated
whereas β-arrestin-dependent pathways would either remain
unaltered or be downregulated as a result of a functional
competition. Interestingly, the activation of ERK5 in CHO-M3
cells overexpressing Gαq was greatly enhanced compared to
control (Figure 4A). On the contrary, the overexpression of
either non-visual β-arrestin, β-arrestin1&2) did not favour ERK5
activation. Coincidently, we demonstrate that silencing of β-
arrestin2 protein expression in NIH-3T3-M1 cells did not affect
carbachol-induced ERK5 activation (Figure 4B-C). These
results confirm that Gαq activation is the predominant event in
the ERK5 pathway whereas β-arrestins are not involved. In
order to further establish the Gαq-biased nature of this pathway
we utilised the angiotensin receptor system, which has been
reported to activate ERK5 through a similar mechanism to that
Figure 3.  Gq-coupled muscarinic receptor-induced activation of the ERK5 pathway does not require receptor
phosphorylation.  Different stable lines of CHO cells (previously characterised in [11]) that stably overexpress wild-type or
phosphorylation-deficient muscarinic M3 receptor (A) and wild-type or phosphorylation-deficient muscarinic M1 receptor (B) were
utilised. All cell lines were transfected with HA-ERK5. Twenty-four hours after transfection, cells were serum-starved for 2h and
stimulated with acetylcholine (100µM) for the indicated times (A) or incubated for 15min with acetylcholine at various concentrations
(B). ERK5 phosphorylation was assessed as in Figure 2. Data (mean +/- SD of 2-3 independent experiments) were normalised
using HA-ERK5 as loading control and expressed as fold-induction over basal conditions or over maximum activation (*p<0.05,
**p<0.005; two-tailed T-test).
doi: 10.1371/journal.pone.0084174.g003
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PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e84174
described for Gq-coupled muscarinic receptors [9]. To this
purpose, we utilised a synthetic angiotensin II ligand (Sar1-Ile4-
Ile8 (SII) AngII) that displays biased properties towards β-
arrestin pathways and has been previously reported to activate
MAPK pathways in certain contexts [13]. As shown in Figure
5A, the ERK5 pathway is not activated by SII as compared to
the natural ligand angiotensin II in primary cardiac fibroblasts.
Interestingly, the β-arrestin-biased ligand was able to promote
the activation of ERK1/2, which indicates the occurrence of
alternative mechanisms for the activation of different MAPK
pathways (Figure 5B). Collectively, these results suggest that
the mechanism for ERK5 activation by model Gq-coupled
receptors is Gαq-biased.
Discussion
The biological functions of GPCR are being currently revised
in the light of novel findings on the ability of β-arrestins to
promote signalling independently of G proteins. For instance,
the activation of ERK1/2 by angiotensin II has been reported as
dual; one initial and rapid stage (after 2 minutes) driven by Gαq
and a later and more sustained activation (after 10 minutes)
driven by arrestins after receptor internalization [4]. Since
ERK5 phosphorylation by Gq-coupled GPCR occurs at a
relatively late stage after receptor activation (usually peaking
around 15/30 minutes [8]) it was tempting to suggest an
involvement of β-arrestin through mechanisms dependent on
receptor phosphorylation and internalization. In the same lines,
neutrophin-induced ERK5 activation in neurons has been
shown to require the internalization of the p62/PKCζ complex
[19]. However, our results clearly show that activation of ERK5
by muscarinic M1/M3 receptors does not seem to involve
receptor internalization, which is one of the mechanisms for β-
arrestin to initiate signalling. The possibility remained that a β-
arrestin-mediated event occurred at the plasma membrane.
However, we found that phosphorylation-deficient muscarinic
Figure 4.  β-arrestins are not involved in ERK5 activation by Gq-coupled muscarinic receptors.  (A) CHO cells stably
expressing wild-type muscarinic M3 receptor (CHO-M3 cells) were transfected with cDNAs encoding for HA-ERK5 and either
pcDNA3, Gαq, β-arrestin1-Flag or β-arrestin2-GFP. Twenty-four hours after transfection, cells were serum-starved for 2h and
stimulated with carbachol (10µM) for the indicated times. ERK5 phosphorylation was assessed as in Figure 2. Data (mean +/- SEM
of 3 independent experiments) were normalised using HA-ERK5 as loading control and expressed as fold-induction over basal
conditions (*p<0.05, **p<0.005, two-tailed T-test). Gαq, β-arrestin1-Flag and β-arrestin2-GFP, and α-tubulin expression levels were
assessed with specific antibodies. (B) NIH-3T3-M1 cells were transfected with siRNA oligonucleotides targeting β-arrestin2 or non-
targeting scrambled oligonucleotides (100nM) as detailed in the Materials and Methods section. After 72h of incubation, cells were
serum-starved for 5h and challenged with carbachol (10µM) for the indicated times. Endogenous ERK5 phosphorylation was
assessed in cell lysates with a phospho-ERK5 specific antibody. Total ERK5 appears as a double band corresponding to basal
(lower) and hyper-phosphorylated (upper) kinase. A representative blot for 3 independent experiments with similar results is shown.
(C) β-arrestin2 expression levels were also determined and quantified to estimate the overall efficiency of protein silencing. Data
(mean +/- SEM of 3 independent experiments) were normalised using α-tubulin as loading control and expressed as the relative
difference (%) to β-arrestin2 protein levels in scrambled siRNA-treated cells.
doi: 10.1371/journal.pone.0084174.g004
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receptors that cannot recruit β-arrestin or internalize [11]
managed to enhance ERK5 activation in comparison to wild-
type receptors. Additionally, a β-arrestin-biased angiotensin
receptor ligand failed to activate ERK5 in cardiac fibroblasts.
On the contrary, we demonstrate that the overexpression of
Gαq, but not that of β-arrestin1 or 2, greatly potentiates ERK5
activation by Gq-coupled GPCR whereas this cascade is not
affected by β-arrestin2 knockdown, thus suggesting that the
activation of the ERK5 pathway is independent of β-arrestin
and displays Gαq-biased properties. Thus, we propose that the
unique properties of the Gαq/ERK5 pathway, where Gαq acts
as a scaffold [8] (a role usually assigned to β-arrestin), could
represent a possible common mechanism for Gαq-bias. The
activation of several families of MAPK by GPCRs have been
shown to require β-arrestin-signalling to some degree and in
certain contexts, either through direct interaction between
MAPK cascade components and β-arrestin [20–22], or being
activated downstream β-arrestin-initiated pathways [3].
Alternatively, our results on the Gαq-biased nature of the ERK5
pathway are consistent with reports for Gq-coupled muscarinic
receptors [14], showing that the activation of the ERK1/2 family
is primarily Gαq- and not β-arrestin-dependent.
The determination of the biased properties of some agonist/
receptor systems is crucial to understand the functional
diversity of GPCRs involved in pathological contexts. A specific
new class of biased drugs against the AT1 type II receptor has
been developed with promising results in a cardiovascular
setting [23]. In these lines, it is tempting to suggest that the
Gαq-biased properties of the ERK5 pathway could further our
understanding of angiotensin II-promoted cardiac hypertrophy,
where this pathway was recently shown to be relevant [9], and
potentially contribute to the fine tuning of therapeutic
interventions.
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Figure 5.  ERK5 is not activated by a β-arrestin-biased agonist in cardiac fibroblasts.  Neonatal mouse cardiac fibroblasts
were challenged with angiotensin (AngII, 100nM) or Sar1-Ile4-Ile8-AngII (SII, 10µM), for the indicated times. Endogenous ERK5 (A)
or ERK1/2 (B) activation was determined in cell lysates with phospho-specific antibodies. Data (mean +/- SEM of 3 independent
experiments) were normalised using total ERK5 or ERK1/2 as loading controls and expressed as fold induction compared with the
absence of agonist (*p<0.05, **p<0.005, two tailed T-test).
doi: 10.1371/journal.pone.0084174.g005
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